JPMorgan H&Q Healthcare Conference
Medarex, Genmab, OGS Launch Bid For Breast Cancer Therapies
By Randall Osborne
Thursday, January 10, 2002
While attendees of the annual JPMorgan H&Q Healthcare Conference scurried through the hallways of the Westin St. Francis hotel here, transgenic mouse company Medarex Inc. let loose a box full of news, including a three-way deal against breast cancer that is the fulfillment of the original promise of genomics and proteomics to turn target discovery into product development, said Donald Drakeman, president and CEO.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.